David C. Klonoff

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

David C. Klonoff, John B. Buse, Loretta L. Nielsen et al. · Current Medical Research and Opinion · 2007 · 698 citations

Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia

Richard M. Bergenstal, David C. Klonoff, Satish K. Garg et al. · New England Journal of Medicine · 2013 · 648 citations

COVID-19 Pandemic: Impact of Quarantine on Medical Students’ Mental Wellbeing and Learning Behaviors

Sultan Ayoub Meo, Abdulelah Adnan Abukhalaf, Ali Abdullah Alomar et al. · Pakistan Journal of Medical Sciences · 2020 · 311 citations · Full text

Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP)

Richard M. Bergenstal, Andrew Ahmann, Timothy S. Bailey et al. · Diabetes Technology & Therapeutics · 2013 · 294 citations

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

John B. Buse, David C. Klonoff, Loretta L. Nielsen et al. · Clinical Therapeutics · 2007 · 278 citations

Obesity, Metabolic Syndrome, Interim Analysis +10